Relmada Therapeutics Inc (NASDAQ: RLMD) is -0.13% lower on its value in year-to-date trading and has touched a low of $0.24 and a high of $4.47 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RLMD stock was last observed hovering at around $0.60 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $0.52, the stock is 20.13% and 45.68% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.14 million and changing -13.02% at the moment leaves the stock -66.11% off its SMA200. RLMD registered -84.45% loss for a year compared to 6-month loss of -82.75%. The firm has a 50-day simple moving average (SMA 50) of $0.35646 and a 200-day simple moving average (SMA200) of $1.532145.
The stock witnessed a 37.38% gain in the last 1 month and extending the period to 3 months gives it a 65.38%, and is 20.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 22.61% over the week and 27.70% over the month.
Relmada Therapeutics Inc (RLMD) has around 17 employees, a market worth around $17.24M and $0.00M in sales. Distance from 52-week low is 116.01% and -88.38% from its 52-week high. The company has generated returns on investments over the last 12 months (-337.38%).
The EPS is expected to grow by 27.17% this year
56.0 institutions hold shares in Relmada Therapeutics Inc (RLMD), with institutional investors hold 40.34% of the company’s shares. The shares outstanding are 33.19M, and float is at 27.81M with Short Float at 7.32%. Institutions hold 33.47% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 1.26 million shares valued at $3.77 million. The investor’s holdings represent 16.6593 of the RLMD Shares outstanding. As of 2024-06-30, the second largest holder is DEEP TRACK CAPITAL, LP with 1.23 million shares valued at $3.7 million to account for 16.3686 of the shares outstanding. The other top investors are VESTAL POINT CAPITAL, LP which holds 1.2 million shares representing 15.9076 and valued at over $3.6 million, while ACADIAN ASSET MANAGEMENT LLC holds 15.8192 of the shares totaling 1.19 million with a market value of $3.58 million.
Relmada Therapeutics Inc (RLMD) Insider Activity
The most recent transaction is an insider purchase by Kelly Paul Edward, the company’s Chief Operating Officer. SEC filings show that Kelly Paul Edward bought 200,000 shares of the company’s common stock on May 16 ’25 at a price of $0.43 per share for a total of $86060.0. Following the purchase, the insider now owns 0.41 million shares.
Relmada Therapeutics Inc disclosed in a document filed with the SEC on May 19 ’25 that Shenouda Maged (Chief Financial Officer) bought a total of 90,000 shares of the company’s common stock. The trade occurred on May 19 ’25 and was made at $0.49 per share for $43686.0. Following the transaction, the insider now directly holds 0.23 million shares of the RLMD stock.
Still, SEC filings show that on May 20 ’25, Shenouda Maged (Chief Financial Officer) acquired 60,000 shares at an average price of $0.52 for $31422.0. The insider now directly holds 288,335 shares of Relmada Therapeutics Inc (RLMD).
